NYSE:ANVS
Annovis Bio, Inc. Stock News
$8.31
+0.280 (+3.49%)
At Close: May 17, 2024
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease
07:30am, Wednesday, 20'th Mar 2024
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced succe
$10 Biotech Stock Wall Street Says Will Be Up Over 200% This Year
09:11am, Friday, 15'th Mar 2024
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored) Are you ready for retirement?
Sell Signal: 3 Stocks to Unload Before the Bubble Bursts
03:33pm, Wednesday, 06'th Mar 2024
As the saying goes, what goes up must come down. This adage holds true for three stocks.
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
08:00am, Tuesday, 27'th Feb 2024
MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel p
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's Disease
07:30am, Wednesday, 14'th Feb 2024
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last pa
3 Growth Stocks to Sell in February Before They Bottom
04:06pm, Monday, 12'th Feb 2024
February triggered a rollercoaster ride through the stock market's twists and turns. Amidst the cacophony of growth stocks to sell, three names echo the market with a hint of fundamental caution.
Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
09:06am, Monday, 12'th Feb 2024
A small sample of patient anecdotes on the internet suggest that buntanetap has some degree of underlying activity in Parkinson's disease (PD). 24-38% of patient anecdotes report a noticeable/measurab
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company's Portfolio
08:00am, Tuesday, 30'th Jan 2024
MALVERN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing o
Annovis Bio Refines Timeline for Parkinson's Phase III Study Data Announcement
08:00am, Wednesday, 24'th Jan 2024
MALVERN, Pa., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, has announced a postpo
Alzheimer's Disease Drug Development: Another Lost Year
03:58am, Tuesday, 05'th Dec 2023
Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
12:53pm, Friday, 01'st Dec 2023
Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
Annovis (ANVS) AD Study to Continue as Planned, Shares Rise
02:16pm, Friday, 13'th Oct 2023
Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III study in Alzheimer's Disease is sufficiently powered to continue as planned without any ad
Top trending biotech stocks: ANVS, MTNB, AVTX, TPST
11:26am, Thursday, 12'th Oct 2023
Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's
3 Biotech Stocks to Buy Before Drug Trials End
12:56pm, Friday, 28'th Jul 2023
Clinical trials can be like a tightrope over a minefield for biotech investors. Only a fraction of drugs even succeed through clinical trials to receive FDA approval.
New Strong Buy Stocks for April 21st
08:22am, Friday, 21'st Apr 2023
WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.